Consulting in Medical Device


  • Regulatory strategy (initial FDA contacts, pre-submissions, IDE submissions, device classification, appropriate regulatory submission)
  • Regulatory submissions: US FDA, EU, Canada, Asia/Pacific, , Rest of World (RoW)
  • Product labeling and packaging development and/or review
  • Coordinate product testing (biocompatibility, electrical safety/EMC, biocompatibility, sterilization validation)
  • Regulatory intelligence and guidance interpretation

Quality Systems/Compliance:

  • Quality System definition and implementation
  • Compliance audits and internal audits
  • Post-market Compliance communications: Responses to 483s and Warning Letters, Field Actions (recalls, market withdrawals, field corrections), MDR/Adverse Event reporting
  • Training: develop training materials, coordinate/deliver employee training sessions

Design Control:

  • Develop/review/audit Design History Files, Technical Files, Design Dossiers
  • Testing coordination: Electrical safety, materials characterization, biocompatibility, shipping/packaging

Clinical Studies:

  • Testing coordination: Electrical safety, materials characterization, biocompatibility, shipping/packaging
  • Clinical trial strategy, protocol development and/or review
  • IRB submissions
  • Clinical trial monitoring

Consulting in Pharma/Biotech

  • Interpretation of EU and USA and Japan/Korea/Canadian regulations and guidlines
  • Science-based strategies for addressing all technical aspects of drug development (labeling, chemistry/manufacturing, preclinical , clinical)
  • Planning of pharmaceutical, toxicology and clinical development programs
  • Identification and monitoring of suitable and reliable partners to carry out the required development work
  • Protocol development and project implementation
  • Clinical phase I-IV support
  • Paediatric Investigational Plans (PIPs)
  • Orphan Drug Designations
  • CTAs/INDs and eCTD/MAAs/NDAs/BLAs and global GCP/GLP/GMP audits
  • eCTD dossier prepatation and submission
  • Preparation EU or US or EU/US "Application for Designation as Orphan Medicinal Product"
  • Pre-submission meeting with the EMA and finalization of documents
  • Compilation and Submission of Orphan Drug Dossier to the EMA
  • Developing orphan drugs is always a challenge for different reasons, among which are precisely defining the condition through clinical symptoms & signs, physiology and biochemistry, and hence deciding on the eligibility of the patient for treatment.
  • Conducting studies of test drug against controls such as placebo may not be ethical, and against a comparatorproblematic, where there is an existing an unmet medical need and there is no "gold standard" of treatment.
  • The small numbers of patients raises questions over reaching justifiable conclusions on efficacy and safety.

Marketing Authorisation of Orphan Drug

Table Representative Orphan Drug Submissions, starting with application for designation

Growth failure

Pre-submission meeting EMA, and Rapporteurs, Prepare Strategy, write,compile and submit MAA/CTD. Change designation during MAA procedure: Unprecedented pioneering orphan strategy, Clarification meetings Rapporteurs.

Severe, debilitating inflamation (Granulomatosis)

Presubmission meedting EMA, andRapporteurs, Prepare strategy, writge, compile and submit MAA/CTD


PIP submission, Protocol Assistance, SME meetings

Content Disclaimer

Contents in our website are from external websites. Links to and content from external website are provided for the convenience of users. takes no responsibility for the content of such links and websites.